Antidiabetic interaction warning

Pioglitazone is licensed for use as monotherapy, with metformin and/or a sulfonylurea, and with insulin | SCIENCE PHOTO LIBRARY
Pioglitazone is licensed for use as monotherapy, with metformin and/or a sulfonylurea, and with insulin | SCIENCE PHOTO LIBRARY

The MHRA has reminded prescribers that combined use of pioglitazone and insulin may be associated with an increased risk of cardiac failure, especially in patients with underlying risk factors for this condition.

If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain, and oedema. Pioglitazone should be discontinued if any deterioration in cardiac status occurs.

Rosiglitazone, another member of the thiazolidinedione class, was withdrawn in 2010 in light of evidence linking it to adverse cardiovascular outcomes.

Further information: MHRA

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases